MRGPRX2 and rosacea: Our study provided in-depth phenotypic and mechanistic evidence on the protective effect of novel MRGPRX2/B2 antagonist GE1111 in attenuating LL-37-induced rosacea-like inflammation and compound 48/80-induced itch in mice.